Upgrade to SI Premium - Free Trial

Rigel Pharmaceuticals (RIGL)

49.53 +0.65 (1.33%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Rigel to present pralsetinib cancer data at ESMO Congress 2026 October 19, 2026 8:06 AM - StreetInsider Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 October 19, 2026 8:05 AM - PR NewsWire Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) October 2, 2026 8:05 AM - PR NewsWire Rigel Pharmaceuticals (RIGL) PT Raised to $49 at Piper Sandler August 17, 2026 7:43 AM - StreetInsider Rigel Pharmaceuticals (RIGL) PT Raised to $85 at H.C. Wainwright August 17, 2026 6:45 AM - StreetInsider Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC August 14, 2026 10:25 AM - SEC Filing Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P. August 13, 2026 9:00 AM - SEC Filing Rigel launches breast cancer drug Veppanu at $29,400 per month August 13, 2026 8:05 AM - StreetInsider Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer August 13, 2026 8:05 AM - PR NewsWire Form S-8 RIGEL PHARMACEUTICALS August 4, 2026 4:37 PM - SEC Filing Form 8-K RIGEL PHARMACEUTICALS For: Aug 04 August 4, 2026 4:10 PM - SEC Filing Form 10-Q RIGEL PHARMACEUTICALS For: Jun 30 August 4, 2026 4:07 PM - SEC Filing Rigel Pharmaceuticals (RIGL) Tops Q2 EPS by 67c; Offers Guidance August 4, 2026 4:05 PM - StreetInsider Rigel Reports Second Quarter 2026 Financial Results August 4, 2026 4:01 PM - PR NewsWire Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results July 28, 2026 8:05 AM - PR NewsWire Full Article List